VolitionRx Rolls Out Automated Nu.Q Vet Cancer Test Across 10 Fujifilm Labs in Japan
VolitionRx completed validation of its chemiluminescent immunoassay-based Nu.Q® Vet Cancer Test for full automation on Fujifilm Vet Systems’ IDS i10 analyzer in Japan, enabling high-throughput testing across 10 central labs. With over 1,700 veterinary hospitals registered and a 7 million canine population, the automated platform targets rapid expansion and revenue growth.
1. Validation and Automation Completion
VolitionRx finalized validation and verification of its chemiluminescent immunoassay version of the Nu.Q® Vet Cancer Test on Fujifilm Vet Systems’ IDS i10 automated analyzer, replacing manual plate processes in central laboratories.
2. Market Reach and Adoption
Since its July 2024 launch, over 1,700 veterinary hospitals in Japan have registered to use the Nu.Q® Vet Cancer Test, tapping into a canine population of approximately 7 million for early cancer screening.
3. Revenue Opportunity
Under a supply agreement, Fujifilm Vet Systems will distribute and perform the automated test across its network of 10 central reference laboratories nationwide, positioning VolitionRx to capture significant service revenues in Japan.
4. Technology Synergy
The IDS i10 platform used for the automated vet cancer test is the same analyzer deployed for VolitionRx’s human Nu.Q® Cancer, NETs and Discover products, demonstrating cross-segment operational efficiencies.